Annual Cash & Cash Equivalents
$137.64 M
-$160.76 M-53.87%
December 31, 2023
Summary
- As of February 27, 2025, CPRX annual cash & cash equivalents is $137.64 million, with the most recent change of -$160.76 million (-53.87%) on December 31, 2023.
- During the last 3 years, CPRX annual cash & cash equivalents has risen by +$7.40 million (+5.68%).
- CPRX annual cash & cash equivalents is now -53.87% below its all-time high of $298.39 million, reached on December 31, 2022.
Performance
CPRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$442.33 M
+$66.64 M+17.74%
September 30, 2024
Summary
- As of February 27, 2025, CPRX quarterly cash and cash equivalents is $442.33 million, with the most recent change of +$66.64 million (+17.74%) on September 30, 2024.
- Over the past year, CPRX quarterly cash and cash equivalents has increased by +$321.36 million (+265.65%).
- CPRX quarterly cash and cash equivalents is now at all-time high.
Performance
CPRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CPRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -53.9% | +265.6% |
| 3 y3 years | +5.7% | +185.7% |
| 5 y5 years | +731.2% | +883.3% |
CPRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -53.9% | at low | at high | +265.6% |
| 5 y | 5-year | -53.9% | +53.8% | at high | +394.2% |
| alltime | all time | -53.9% | >+9999.0% | at high | >+9999.0% |
Catalyst Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $442.33 M(+17.7%) |
| Jun 2024 | - | $375.69 M(+21.0%) |
| Mar 2024 | - | $310.41 M(+125.5%) |
| Dec 2023 | $137.64 M(-53.9%) | $137.64 M(+13.8%) |
| Sep 2023 | - | $120.97 M(-32.3%) |
| Jun 2023 | - | $178.79 M(+20.6%) |
| Mar 2023 | - | $148.25 M(-50.3%) |
| Dec 2022 | $298.39 M(+74.0%) | $298.39 M(+16.5%) |
| Sep 2022 | - | $256.06 M(+21.4%) |
| Jun 2022 | - | $210.91 M(+18.2%) |
| Mar 2022 | - | $178.37 M(+4.0%) |
| Dec 2021 | $171.44 M(+31.6%) | $171.44 M(+10.7%) |
| Sep 2021 | - | $154.84 M(+14.4%) |
| Jun 2021 | - | $135.29 M(+6.3%) |
| Mar 2021 | - | $127.33 M(-2.2%) |
| Dec 2020 | $130.24 M(+45.5%) | $130.24 M(+11.2%) |
| Sep 2020 | - | $117.11 M(+1.8%) |
| Jun 2020 | - | $115.05 M(+13.1%) |
| Mar 2020 | - | $101.75 M(+13.7%) |
| Dec 2019 | $89.51 M(+440.5%) | $89.51 M(+99.0%) |
| Sep 2019 | - | $44.98 M(+92.1%) |
| Jun 2019 | - | $23.42 M(+22.7%) |
| Mar 2019 | - | $19.08 M(+15.2%) |
| Dec 2018 | $16.56 M(-71.2%) | $16.56 M(+56.0%) |
| Sep 2018 | - | $10.62 M(+7.4%) |
| Jun 2018 | - | $9.89 M(-49.6%) |
| Mar 2018 | - | $19.60 M(-65.9%) |
| Dec 2017 | $57.50 M(+313.9%) | $57.50 M(+684.5%) |
| Sep 2017 | - | $7.33 M(-14.6%) |
| Jun 2017 | - | $8.58 M(-14.0%) |
| Mar 2017 | - | $9.98 M(-28.2%) |
| Dec 2016 | $13.89 M(-50.8%) | $13.89 M(-21.2%) |
| Sep 2016 | - | $17.64 M(-5.8%) |
| Jun 2016 | - | $18.72 M(-15.8%) |
| Mar 2016 | - | $22.23 M(-21.3%) |
| Dec 2015 | $28.23 M | $28.23 M(-13.8%) |
| Sep 2015 | - | $32.75 M(-12.0%) |
| Jun 2015 | - | $37.22 M(-9.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $41.32 M(+354.3%) |
| Dec 2014 | $9.10 M(+310.5%) | $9.10 M(-19.2%) |
| Sep 2014 | - | $11.26 M(-23.9%) |
| Jun 2014 | - | $14.80 M(+1280.1%) |
| Mar 2014 | - | $1.07 M(-51.6%) |
| Dec 2013 | $2.22 M(+57.2%) | $2.22 M(-82.9%) |
| Sep 2013 | - | $12.96 M(+1374.6%) |
| Jun 2013 | - | $879.10 K(+36.1%) |
| Mar 2013 | - | $646.00 K(-54.2%) |
| Dec 2012 | $1.41 M(-76.6%) | $1.41 M(-88.2%) |
| Sep 2012 | - | $11.97 M(+59.3%) |
| Jun 2012 | - | $7.51 M(+59.1%) |
| Mar 2012 | - | $4.72 M(-21.7%) |
| Dec 2011 | $6.03 M(+10.1%) | $6.03 M(+180.2%) |
| Sep 2011 | - | $2.15 M(-36.8%) |
| Jun 2011 | - | $3.41 M(-50.4%) |
| Mar 2011 | - | $6.87 M(+25.5%) |
| Dec 2010 | $5.48 M(-29.6%) | $5.48 M(-12.4%) |
| Sep 2010 | - | $6.25 M(+11.4%) |
| Jun 2010 | - | $5.61 M(-17.0%) |
| Mar 2010 | - | $6.76 M(-13.1%) |
| Dec 2009 | $7.78 M(-33.9%) | $7.78 M(+58.4%) |
| Sep 2009 | - | $4.91 M(-21.6%) |
| Jun 2009 | - | $6.27 M(-29.8%) |
| Mar 2009 | - | $8.93 M(-24.1%) |
| Dec 2008 | $11.77 M(-26.2%) | $11.77 M(-21.7%) |
| Sep 2008 | - | $15.03 M(+14.9%) |
| Jun 2008 | - | $13.08 M(-11.1%) |
| Mar 2008 | - | $14.72 M(-7.7%) |
| Dec 2007 | $15.94 M(-22.0%) | $15.94 M(-5.6%) |
| Sep 2007 | - | $16.89 M(-4.1%) |
| Jun 2007 | - | $17.60 M(-7.7%) |
| Mar 2007 | - | $19.06 M(-6.7%) |
| Dec 2006 | $20.43 M(+2550.1%) | $20.43 M(+580.4%) |
| Sep 2006 | - | $3.00 M(+826.4%) |
| Jun 2006 | - | $324.20 K(-58.0%) |
| Dec 2005 | $771.10 K(+319.3%) | $771.10 K(+319.3%) |
| Dec 2004 | $183.90 K(+71.7%) | $183.90 K |
| Dec 2002 | $107.10 K | - |
FAQ
- What is Catalyst Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Catalyst Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Catalyst Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of CPRX is $137.64 M
What is the all time high annual cash & cash equivalents for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual cash & cash equivalents is $298.39 M
What is Catalyst Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, CPRX annual cash & cash equivalents has changed by -$160.76 M (-53.87%)
What is Catalyst Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CPRX is $442.33 M
What is the all time high quarterly cash and cash equivalents for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly cash and cash equivalents is $442.33 M
What is Catalyst Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, CPRX quarterly cash and cash equivalents has changed by +$321.36 M (+265.65%)